Lords Mark Industries has successfully completed Phase I of its expansion plan at its Silvassa facility, achieving completion nearly three months ahead of its originally committed December 2026 timeline. According to the company's announcement on September 16, 2026, the newly expanded production line is scheduled to commence commercial operations from October 11, 2026. This early completion demonstrates the company's operational efficiency and commitment to meeting its expansion targets, positioning it to strengthen its presence in the surgical and orthopaedic medical devices market.
The surgical and orthopaedic product portfolio has experienced significant growth, expanding from 36 to 54 SKUs through the addition of 18 new products. As reported by the company, these new SKUs are currently progressing through the US FDA approval process and are anticipated to receive clearance before December 2026. The existing portfolio of 36 surgical and orthopaedic products already holds US FDA approval, while the newly introduced 18 SKUs are undergoing regulatory clearance. This expansion significantly broadens the company's product offerings in the medical devices sector and supports its long-term vision of becoming a recognized global player in the medical devices industry.
The completion of Phase I expansion positions Lords Mark Industries to strengthen its presence in the surgical and orthopaedic medical devices market across domestic and international healthcare ecosystems. According to the company's announcement, the expanded facility will support the commercial launch of the newly approved products, potentially enhancing the company's competitive position in the US market. The accelerated commercial launch in October 2026 reinforces the company's manufacturing capabilities and broadens its market reach, with specific risks associated with the US FDA approval timeline for the 18 new SKUs and contingency plans if clearance is delayed beyond December 2026.
